1
|
Li D, Zhang Z, Li Y, Wang X, Zhong H, Yang H, Xi Y, Liu H, Shen A, Hu Y. Discovery of ( S)- N-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6 H)-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate. J Med Chem 2023; 66:7016-7037. [PMID: 37184921 DOI: 10.1021/acs.jmedchem.3c00525] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
A novel series of benzamide derivatives were successively designed and synthesized prepared from the pyridazinone scaffold. Among them, (S)-17b, demonstrated potent inhibitory activity in vitro toward human class I HDAC isoforms and human myelodysplastic syndrome (SKM-1) cell line. Also, (S)-17b strongly increased the intracellular level of acetyl-histone H3 and P21 simultaneously and effectively induced G1 cell cycle arrest and apoptosis. Through oral dosing in SKM-1 xenograft models, (S)-17b exhibited excellent in vivo antitumor activity. In addition, compound (S)-17b showed better antitumor efficacy on mouse models with intact immune system than those with thymus deficiencies. Furthermore, this compound displayed a favorable pharmacokinetic profile in ICR mice and SD rat, respectively, minimal metabolic property differences among hepatocytes from five species, and a low inhibition upon the human ether-a-go-go (hERG) channel with an IC50 value of 34.6 μΜ. This novel compound (S)-17b may serve as a new drug candidate for further investigation.
Collapse
Affiliation(s)
- Daqiang Li
- State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
| | - Zhuo Zhang
- State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 110039, China
| | - Yalei Li
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
| | - Xinyi Wang
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 110039, China
| | - Hanyue Zhong
- State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 110039, China
| | - Huajie Yang
- State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
| | - Yong Xi
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
| | - Hongchun Liu
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
| | - Aijun Shen
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 110039, China
- Lingang Laboratory, Shanghai 200031, China
| | - Youhong Hu
- State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China
- University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 110039, China
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China
| |
Collapse
|
2
|
Ioppolo A, Eccles M, Groth D, Verdile G, Agostino M. Evaluation of Virtual Screening Strategies for the Identification of γ-Secretase Inhibitors and Modulators. Molecules 2021; 27:176. [PMID: 35011410 PMCID: PMC8746326 DOI: 10.3390/molecules27010176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 12/23/2021] [Accepted: 12/24/2021] [Indexed: 11/17/2022] Open
Abstract
γ-Secretase is an intramembrane aspartyl protease that is important in regulating normal cell physiology via cleavage of over 100 transmembrane proteins, including Amyloid Precursor Protein (APP) and Notch family receptors. However, aberrant proteolysis of substrates has implications in the progression of disease pathologies, including Alzheimer's disease (AD), cancers, and skin disorders. While several γ-secretase inhibitors have been identified, there has been toxicity observed in clinical trials associated with non-selective enzyme inhibition. To address this, γ-secretase modulators have been identified and pursued as more selective agents. Recent structural evidence has provided an insight into how γ-secretase inhibitors and modulators are recognized by γ-secretase, providing a platform for rational drug design targeting this protease. In this study, docking- and pharmacophore-based screening approaches were evaluated for their ability to identify, from libraries of known inhibitors and modulators with decoys with similar physicochemical properties, γ-secretase inhibitors and modulators. Using these libraries, we defined strategies for identifying both γ-secretase inhibitors and modulators incorporating an initial pharmacophore-based screen followed by a docking-based screen, with each strategy employing distinct γ-secretase structures. Furthermore, known γ-secretase inhibitors and modulators were able to be identified from an external set of bioactive molecules following application of the derived screening strategies. The approaches described herein will inform the discovery of novel small molecules targeting γ-secretase.
Collapse
Affiliation(s)
- Alicia Ioppolo
- Curtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia; (A.I.); (M.E.); (D.G.); (G.V.)
| | - Melissa Eccles
- Curtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia; (A.I.); (M.E.); (D.G.); (G.V.)
| | - David Groth
- Curtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia; (A.I.); (M.E.); (D.G.); (G.V.)
| | - Giuseppe Verdile
- Curtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia; (A.I.); (M.E.); (D.G.); (G.V.)
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia
| | - Mark Agostino
- Curtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia; (A.I.); (M.E.); (D.G.); (G.V.)
- Curtin Institute for Computation, Curtin University, Bentley, WA 6102, Australia
| |
Collapse
|
3
|
Jothi S, Vuppu S. An industrial perspective fermentative bioreduction of aromatic ketones by Penicillium rubens VIT SS1 and Penicillium citrinum VIT SS2. BIOCATAL BIOTRANSFOR 2021. [DOI: 10.1080/10242422.2021.1963239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Saravanan Jothi
- School of Biosciences and Technology, VIT University, Vellore, India
- R&D, Iosynth Labs Private Limited, Bangalore, India
| | - Suneetha Vuppu
- School of Biosciences and Technology, VIT University, Vellore, India
| |
Collapse
|
4
|
Mandal M, Buevich A, Caldwell JP, Hyde L, Huang X, Liu X, McKittrick B, Mazzola RD, Pissarnitski D, Palani A, Zhang L, Parker E, Xiao L, Rindgen D, Zhu Z. Generation of Leads for γ-Secretase Modulation. J Med Chem 2020; 63:8216-8230. [DOI: 10.1021/acs.jmedchem.0c00446] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Mihirbaran Mandal
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Alexei Buevich
- Department of NMR Structure Elucidation, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - John P. Caldwell
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Lynn Hyde
- Department of Neuroscience, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xianhai Huang
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xiaoxiang Liu
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Brian McKittrick
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Robert D. Mazzola
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Dmitri Pissarnitski
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Anandan Palani
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Lili Zhang
- Department of Neuroscience, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Eric Parker
- Department of Neuroscience, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Li Xiao
- Department of Modeling and Informatics, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Diane Rindgen
- Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Zhaoning Zhu
- Department of Medicinal Chemistry, Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
5
|
Control of enantioselectivity in the enzymatic reduction of halogenated acetophenone analogs by substituent positions and sizes. Tetrahedron Lett 2020. [DOI: 10.1016/j.tetlet.2020.151820] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
6
|
Vanda D, Zajdel P, Soural M. Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases. Eur J Med Chem 2019; 181:111569. [DOI: 10.1016/j.ejmech.2019.111569] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Revised: 06/26/2019] [Accepted: 07/28/2019] [Indexed: 12/18/2022]
|
7
|
Zhao Z, Pissarnitski DA, Huang X, Palani A, Zhu Z, Greenlee WJ, Hyde LA, Song L, Terracina G, Zhang L, Parker EM. Discovery of a Tetrahydrobenzisoxazole Series of γ-Secretase Modulators. ACS Med Chem Lett 2017; 8:1002-1006. [PMID: 29057041 DOI: 10.1021/acsmedchemlett.7b00178] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2017] [Accepted: 09/19/2017] [Indexed: 11/29/2022] Open
Abstract
The design and synthesis of a new series of tetrahydrobenzisoxazoles as modulators of γ-secretase activity and their structure-activity relationship (SAR) will be detailed. Several compounds are active γ-secretase modulators (GSMs) with good to excellent selectivity for the reduction of Aβ42 in the cellular assay. Compound 14a was tested in vivo in a nontransgenic rat model and was found to significantly reduce Aβ42 in the CNS compartment compared to vehicle-treated animals (up to 58% reduction of cerebrospinal fluid Aβ42 as measured 3 h after an acute oral dosing at 30 mg/kg).
Collapse
Affiliation(s)
- Zhiqiang Zhao
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Dmitri A. Pissarnitski
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xianhai Huang
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Anandan Palani
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Zhaoning Zhu
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - William J. Greenlee
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | | | | | | | | | | |
Collapse
|
8
|
γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer’s Disease. TOPICS IN MEDICINAL CHEMISTRY 2017. [DOI: 10.1007/7355_2016_19] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
9
|
Wang L, Liu N, Dai B. Metal-free site-selective C–N bond-forming reaction of polyhalogenated pyridines and pyrimidines. RSC Adv 2015. [DOI: 10.1039/c5ra18653f] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
A metal-free method for highly site-selective C–N bond-formation of polyhalogenated pyridines and pyrimidines is developed.
Collapse
Affiliation(s)
- Lei Wang
- School of Chemistry and Chemical Engineering
- Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan
- Shihezi University
- Shihezi
- China
| | - Ning Liu
- School of Chemistry and Chemical Engineering
- Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan
- Shihezi University
- Shihezi
- China
| | - Bin Dai
- School of Chemistry and Chemical Engineering
- Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan
- Shihezi University
- Shihezi
- China
| |
Collapse
|
10
|
Kobayashi T, Iwama S, Fusano A, Kato Y, Ikeda A, Teranishi Y, Nishihara A, Tobe M. Design and synthesis of an aminopiperidine series of γ-secretase modulators. Bioorg Med Chem Lett 2014; 24:378-81. [DOI: 10.1016/j.bmcl.2013.10.063] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Revised: 10/22/2013] [Accepted: 10/29/2013] [Indexed: 11/28/2022]
|
11
|
Hall A, Patel TR. γ-Secretase modulators: current status and future directions. PROGRESS IN MEDICINAL CHEMISTRY 2014; 53:101-45. [PMID: 24418609 DOI: 10.1016/b978-0-444-63380-4.00003-2] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
This chapter reviews the current status of γ-secretase modulators, highlighting key compounds by each company involved in the area. The review focuses on the three main chemotypes: acids, imidazoles and related derivatives and natural products. A section on chemical biology and ligand-binding site elucidation studies is also included. The primary source of information is drawn from peer reviewed literature as this permits analysis of PK-PD relationships and subsequent comment. Discussion of the patent literature is included for completeness. From this analysis, the key issues and challenges in the area are highlighted. The review concludes with a summary of the clinical development status and comment on future prospects of the field.
Collapse
Affiliation(s)
- Adrian Hall
- Department of Chemistry, Discovery Research, Neuroscience and General Medicine Product Creation Unit, Eisai Ltd., EMEA Knowledge Centre, Mosquito Way, Hatfield, United Kingdom
| | - Toshal R Patel
- Department of BioPharmacology, Discovery Research, Neuroscience and General Medicine Product Creation Unit, Eisai Ltd., EMEA Knowledge Centre, Mosquito Way, Hatfield, United Kingdom
| |
Collapse
|
12
|
Chen JJ, Qian W, Biswas K, Yuan C, Amegadzie A, Liu Q, Nixey T, Zhu J, Ncube M, Rzasa RM, Chavez F, Chen N, DeMorin F, Rumfelt S, Tegley CM, Allen JR, Hitchcock S, Hungate R, Bartberger MD, Zalameda L, Liu Y, McCarter JD, Zhang J, Zhu L, Babu-Khan S, Luo Y, Bradley J, Wen PH, Reid DL, Koegler F, Dean C, Hickman D, Correll TL, Williamson T, Wood S. Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett 2013; 23:6447-54. [DOI: 10.1016/j.bmcl.2013.09.041] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Revised: 09/12/2013] [Accepted: 09/13/2013] [Indexed: 12/20/2022]
|
13
|
Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators. Bioorg Med Chem Lett 2013; 23:4794-800. [PMID: 23890837 DOI: 10.1016/j.bmcl.2013.06.100] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2013] [Revised: 06/28/2013] [Accepted: 06/29/2013] [Indexed: 12/17/2022]
Abstract
The evolution of amide 3 into conformationally restricted bicyclic triazolo-piperidine 14-S as a γ-secretase modulator is described. This is a potential disease modifying anti-Alzheimer's drug which demonstrated high in vitro and in vivo potency against Aβ42 peptide, reduced lipophilicity and enhanced brain free fraction compared to the previous series.
Collapse
|
14
|
Crump CJ, Johnson DS, Li YM. Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry 2013; 52:3197-216. [PMID: 23614767 DOI: 10.1021/bi400377p] [Citation(s) in RCA: 131] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
γ-Secretase is an aspartyl intramembranal protease composed of presenilin, Nicastrin, Aph1, and Pen2 with 19 transmembrane domains. γ-Secretase cleaves the amyloid precursor proteins (APP) to release Aβ peptides that likely play a causative role in the pathogenesis of Alzheimer's disease (AD). In addition, γ-secretase cleaves Notch and other type I membrane proteins. γ-Secretase inhibitors (GSIs) have been developed and used for clinical studies. However, clinical trials have shown adverse effects of GSIs that are potentially linked with nondiscriminatory inhibition of Notch signaling, overall APP processing, and other substrate cleavages. Therefore, these findings call for the development of disease-modifying agents that target γ-secretase activity to lower levels of Aβ42 production without blocking the overall processing of γ-secretase substrates. γ-Secretase modulators (GSMs) originally derived from nonsteroidal anti-inflammatory drugs (NSAIDs) display such characteristics and are the focus of this review. However, first-generation GSMs have limited potential because of the low potency and undesired neuropharmacokinetic properties. This generation of GSMs has been suggested to interact with the APP substrate, γ-secretase, or both. To improve the potency and brain availability, second-generation GSMs, including NSAID-derived carboxylic acid and non-NSAID-derived heterocyclic chemotypes, as well as natural product-derived GSMs have been developed. Animal studies of this generation of GSMs have shown encouraging preclinical profiles. Moreover, using potent GSM photoaffinity probes, multiple studies unambiguously have showed that both carboxylic acid and heterocyclic GSMs specifically target presenilin, the catalytic subunit of γ-secretase. In addition, two types of GSMs have distinct binding sites within the γ-secretase complex and exhibit different Aβ profiles. GSMs induce a conformational change of γ-secretase to achieve modulation. Various models are proposed and discussed. Despite the progress of GSM research, many outstanding issues remain to be investigated to achieve the ultimate goal of developing GSMs as effective AD therapies.
Collapse
Affiliation(s)
- Christina J Crump
- Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center , 1275 York Avenue, New York, New York 10065, United States
| | | | | |
Collapse
|
15
|
Pan S, Ryu N, Shibata T. Ir(I)-catalyzed synthesis of N-substituted pyridones from 2-alkoxypyridines via C-O bond cleavage. Org Lett 2013; 15:1902-5. [PMID: 23540513 DOI: 10.1021/ol400557z] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A cationic Ir(I) complex-catalyzed O-to-N-alkyl migration in 2-alkoxypyridines bearing a secondary alkyl group on the oxygen atom by C-O bond cleavage is described. The present transformation gave various N-alkylpyridones in moderate to good yields. The addition of sodium acetate played a key role in suppressing β-hydrogen elimination.
Collapse
Affiliation(s)
- Shiguang Pan
- Department of Chemistry and Biochemistry, School of Advanced Science and Engineering, Waseda University, Shinjuku, Tokyo 169-8555, Japan
| | | | | |
Collapse
|
16
|
Li H, Qin J, Dhondi P, Zhou W, Vicarel M, Bara T, Cole D, Josien H, Pissarnitski D, Zhu Z, Palani A, Aslanian R, Clader J, Czarniecki M, Greenlee W, Cohen-Williams M, Hyde L, Song L, Zhang L, Chu I, Huang X. The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer’s disease. Bioorg Med Chem Lett 2013; 23:466-71. [DOI: 10.1016/j.bmcl.2012.11.055] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2012] [Revised: 11/10/2012] [Accepted: 11/14/2012] [Indexed: 11/28/2022]
|
17
|
Huang X, Zhou W, Liu X, Li H, Sun G, Mandal M, Vicarel M, Zhu X, Bennett C, McCraken T, Pissarnitski D, Zhao Z, Cole D, Gallo G, Zhu Z, Palani A, Aslanian R, Clader J, Czarniecki M, Greenlee W, Burnett D, Cohen-Williams M, Hyde L, Song L, Zhang L, Chu I, Buevich A. Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease. ACS Med Chem Lett 2012; 3:931-5. [PMID: 24900409 DOI: 10.1021/ml300209g] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2012] [Accepted: 09/04/2012] [Indexed: 01/18/2023] Open
Abstract
Fused oxadiazines (3) were discovered as selective and orally bioavailable γ-secretase modulators (GSMs) based on the structural framework of oxadiazoline GSMs. Although structurally related, initial modifications showed that structure-activity relationships (SARs) did not translate from the oxadiazoline to the oxadiazine series. Subsequent SAR studies on modifications at the C3 and C4 positions of the fused oxadiazine core helped to identify GSMs such as compounds 8r and 8s that were highly efficacious in vitro and in vivo in a number of animal models with highly desirable physical and pharmacological properties. Further improvements of in vitro activity and selectivity were achieved by the preparation of fused morpholine oxadiazines. The shift in specificity of APP cleavage rather than a reduction in overall γ-secretase activity and the lack of changes in substrate accumulation and Notch processing as observed in the animal studies of compound 8s confirm that the oxadiazine series of compounds are potent GSMs.
Collapse
Affiliation(s)
- Xianhai Huang
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Wei Zhou
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Xiaoxiang Liu
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Hongmei Li
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - George Sun
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Mihirbaran Mandal
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Monica Vicarel
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Xiaohong Zhu
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Chad Bennett
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Troy McCraken
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Dmitri Pissarnitski
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Zhiqiang Zhao
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - David Cole
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Gioconda Gallo
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Zhaoning Zhu
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Anandan Palani
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Robert Aslanian
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - John Clader
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Michael Czarniecki
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - William Greenlee
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Duane Burnett
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Mary Cohen-Williams
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Lynn Hyde
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Lixin Song
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Lili Zhang
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Inhou Chu
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Alexei Buevich
- Department
of Medicinal Chemistry, ‡Department of In Vitro Biology, §Department of In Vivo Biology, ∥Drug Metabolism, and ⊥Structual Elucidation, Merck Research Laboratory, 126 East
Lincoln Avenue, Rahway, New Jersey 07065, United States
| |
Collapse
|
18
|
Núñez-Rico JL, Etayo P, Fernández-Pérez H, Vidal-Ferran A. Modular POP Ligands in Rhodium-Mediated Asymmetric Hydrogenation: A Comparative Catalysis Study. Adv Synth Catal 2012. [DOI: 10.1002/adsc.201200477] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
19
|
Huang X, Pissarnitski D, Li H, Asberom T, Josien H, Zhu X, Vicarel M, Zhao Z, Rajagopalan M, Palani A, Aslanian R, Zhu Z, Greenlee W, Buevich A. Efficient synthesis and reaction pathway studies of novel fused morpholine oxadiazolines for use as gamma secretase modulators. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.09.070] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Bischoff F, Berthelot D, De Cleyn M, Macdonald G, Minne G, Oehlrich D, Pieters S, Surkyn M, Trabanco AA, Tresadern G, Van Brandt S, Velter I, Zaja M, Borghys H, Masungi C, Mercken M, Gijsen HJM. Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent γ-Secretase Modulators. J Med Chem 2012; 55:9089-106. [DOI: 10.1021/jm201710f] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Francois Bischoff
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Didier Berthelot
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Michel De Cleyn
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Gregor Macdonald
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Garrett Minne
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Daniel Oehlrich
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Serge Pieters
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Michel Surkyn
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Andrés A. Trabanco
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Gary Tresadern
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Sven Van Brandt
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Ingrid Velter
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Mirko Zaja
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Herman Borghys
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Chantal Masungi
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Marc Mercken
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | - Harrie J. M. Gijsen
- Janssen Research & Development, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| |
Collapse
|
21
|
Mandal M, Lavey C, Buevich AV, Zhu Z, Stamford AW, Liu X. On the power of super acid—iodination of aromatic ring in the presence of imidazole moiety of the potent gamma secretase modulators (GSM) en route to tritium labeling. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.01.085] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
22
|
Pettersson M, Johnson DS, Subramanyam C, Bales KR, am Ende CW, Fish BA, Green ME, Kauffman GW, Lira R, Mullins PB, Navaratnam T, Sakya SM, Stiff CM, Tran TP, Vetelino BC, Xie L, Zhang L, Pustilnik LR, Wood KM, O'Donnell CJ. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators. Bioorg Med Chem Lett 2012; 22:2906-11. [PMID: 22429469 DOI: 10.1016/j.bmcl.2012.02.059] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2012] [Revised: 02/16/2012] [Accepted: 02/17/2012] [Indexed: 12/12/2022]
Abstract
We report the discovery and optimization of a novel series of dihydrobenzofuran amides as γ-secretase modulators (GSMs). Strategies for aligning in vitro potency with drug-like physicochemical properties and good microsomal stability while avoiding P-gp mediated efflux are discussed. Lead compounds such as 35 and 43 have moderate to good in vitro potency and excellent selectivity against Notch. Good oral bioavailability was achieved as well as robust brain Aβ42 lowering activity at 100 mg/kg po dose.
Collapse
Affiliation(s)
- Martin Pettersson
- Neuroscience Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Ueda S, Su M, Buchwald SL. Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles: application to the synthesis of nilotinib. J Am Chem Soc 2012; 134:700-6. [PMID: 22126442 PMCID: PMC3257364 DOI: 10.1021/ja2102373] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The completely N(1)-selective Pd-catalyzed arylation of unsymmetric imidazoles with aryl halides and triflates is described. This study showed that imidazoles have a strong inhibitory effect on the in situ formation of the catalytically active Pd(0)-ligand complex. The efficacy of the N-arylation reaction was improved drastically by the use of a preactivated solution of Pd(2)(dba)(3) and L1. From these findings, it is clear that while imidazoles can prevent binding of L1 to Pd, once the ligand is bound to the metal, these heterocycles do not displace it. The utility of the present catalytic system was demonstrated by the regioselective synthesis of the clinically important tyrosine kinase inhibitor nilotinib.
Collapse
Affiliation(s)
- Satoshi Ueda
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Mingjuan Su
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Stephen L. Buchwald
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139
| |
Collapse
|
24
|
Qin J, Zhou W, Huang X, Dhondi P, Palani A, Aslanian R, Zhu Z, Greenlee W, Cohen-Williams M, Jones N, Hyde L, Zhang L. Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators. ACS Med Chem Lett 2011; 2:471-6. [PMID: 24900332 DOI: 10.1021/ml2000438] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2011] [Accepted: 03/23/2011] [Indexed: 11/29/2022] Open
Abstract
The synthesis and structure-activity relationship of a novel series of pyrazolopyridines are reported. These compounds represent a new class of γ-secretase modulators that demonstrate good in vitro potency in inhibiting Aβ42 production. Examples with statistically significant in vivo efficacy in reducing the production of rat cerebrospinal fluid Aβ42 were also identified.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - William Greenlee
- Department of Medicinal Chemistry, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | | | | | | | | |
Collapse
|
25
|
Pettersson M, Kauffman GW, am Ende CW, Patel NC, Stiff C, Tran TP, Johnson DS. Novel γ-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat 2011; 21:205-26. [PMID: 21231889 DOI: 10.1517/13543776.2011.547479] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION The amyloid precursor protein is first cleaved by β-secretase to generate a 99-residue membrane-bound CTF (C99 or β-CTF), which is subsequently cleaved by γ-secretase to generate amyloid β (Aβ) peptides and the APP intracellular domain. The amyloidogenic Aβ42 has attracted considerable attention because it is thought to be the most pathogenic species associated with Alzheimer's disease progression. New classes of compounds, called γ-secretase modulators (GSMs), have been shown to selectively lower Aβ42 production without shutting down key γ-secretase-dependent signaling pathways. This has become an important therapeutic strategy aimed at modulating Aβ production. AREAS COVERED The progress on the clinical development of γ-secretase inhibitors is briefly covered in this review, followed by a discussion of the potential differentiating attributes of GSMs. Then, the patent literature covering novel GSMs is reviewed, focusing on patents from 2008 to 2010. EXPERT OPINION Much progress has been made in the past 2 years on developing GSMs with improved potency for lowering the production of Aβ42. However, many of these chemotypes are in a challenging chemical space and generally possess higher lipophilicity than most CNS drugs. It will be important to gain a better understanding of the specific target(s) that these GSMs interact with in order to facilitate future drug design efforts.
Collapse
Affiliation(s)
- Martin Pettersson
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern Point Road, Groton, CT 06340, USA
| | | | | | | | | | | | | |
Collapse
|
26
|
Oehlrich D, Berthelot DJC, Gijsen HJM. γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 2010; 54:669-98. [PMID: 21141968 DOI: 10.1021/jm101168r] [Citation(s) in RCA: 127] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Daniel Oehlrich
- Medicinal Chemistry, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
| | | | | |
Collapse
|